ATG5 and pancreatic neoplasm: reported that lucidone treatment enhances chemosensitivity by inhibiting the expression of autophagic proteins (Atg5, Beclin-1, LC3-II, and Vps34) via the inhibition of the HMGB1/RAGE/PI3K/Akt axis in pancreatic cancer cells (26).